Adjuvant WIDER: A phase 3b trial of ribociclib (RIB) + endocrine therapy (ET) as adjuvant treatment (tx) in a close-to-clinical-practice patient (pt) population with HR+/HER2− early breast cancer (EBC).

Authors: Stephanie L. Graff, Fatima Cardoso, Hope S. Rugo, Christine Brezden-Masley, Gustavo Werustsky, Debasish Tripathy, Joyce O'Shaughnessy, Cynthia X. Ma, Michael A. Danso, Yen-Shen Lu, Gul Basaran, Mario Campone, Michelino De Laurentiis, Javier Cortes, Valarie Worthy, Melissa Gao, Benoit Musel, Fen Ye, Kristyn Pantoja, Peter A. Fasching

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps617

Source: Full article

---

Abstract

TPS617